Rent Hoarding Panels for Businesses in Perth — Built for Safety, Style, and Compliance
Renovating or refitting your workspace...
CAR-T Cell Therapy Market: Exploring Potential in Solid Tumors and Beyond
Meticulous Research®—a leading market research company, published a research report titled, ‘CAR T-cell Therapy Market by Brand (Abecma [idecabtagene vicleucel], Breyanzi [lisocabtagene maraleucel], Yescarta [axicabtagene ciloleucel]), Target Antigen (CD, BCMA, HER2), Indication (Lymphoma, ALL, AML, Multiple Myeloma) - Global Forecast to 2030.'According to this latest publication from Meticulous Research®, the CAR T-cell therapy market is projected to reach $51.6 billion by 2030, at a CAGR of 43.3% from 2023 to 2030. The growth of this market is driven by increasing cancer prevalence, a rise in awareness regarding CAR T-cell therapy, and increasing R&D activities and clinical trials. However, the complex manufacturing process and adverse effects of the therapy may restrain the growth of this market. Additionally, a high scope in emerging economies, innovation in CAR T-cell therapies and manufacturing processes are creating opportunities for market growth. Moreover, the high treatment cost of therapy and the lack of skilled professionals are challenging factors for the market.
Download Free PDF Sample Copy of the Report (with COVID-19 Impact Analysis):
https://www.meticulousresearch.com/product/car-t-cell-therapy-market-5508
Scope of the Report:
CAR T-cell Therapy Market Size & Trend Analysis, by Drug Type
- Abecma (idecabtagene vicleucel)
- Breyanzi (lisocabtagene maraleucel)
- Kymriah (tisagenlecleucel)
- Tecartus (brexucabtagene autoleucel)
- Yescarta (axicabtagene ciloleucel)
- Carvykti (ciltacabtagene autoleucel)
- Other Brands
- CD
- BCMA
- HER2
- Other Target Antigens
(Other target antigens include EGFR, GD2, MUC16, Lewis Y, and ROR1)
- Lymphoma
- Acute Lymphoblastic Leukemia
- Multiple Myeloma
- Acute Myeloid Leukemia
- Other Indications
(Other indications include pancreatic cancer, breast cancer, ovarian cancer, scleroderma, HIV/AIDs, and autoimmune diseases.)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
- Latin America
- Middle East & Africa
To Gain More Insights into the Market with a Detailed Table of Content and Figures, Click Here:
https://www.meticulousresearch.com/download-sample-report/cp_id=5508
Developments in Cell Therapies to Offer Significant Opportunities for the CAR T-cell Therapy Market Growth
Consistent developments in CAR T-cell therapy at various stages will positively impact its efficacy. Some of these developments include allogeneic CAR T-cell procedures. This procedure avoids the issues with autologous CAR T-cells in harvesting, product variability, long vein-to-vein time, and T-cell dysfunction. This treatment will help to expand the patient category, such as those with low T-cell levels, harvest failures, or who need treatment before autologous CAR T-cells can be manufactured. Another major development is in the viral-vector capacity. The viral-vector capacity constraint and a limited number of third-party suppliers lead to the in-house production of these viral vectors. Also, the lenti or adeno-associated-virus-based approaches are time-consuming and inefficient. Hence, the need for efficient gene-transfer tools enables rapid modification of T-cells with CARs and additional modifications such as removing donor T-cell receptors, adding on-off switches that can turn off the CAR T to prevent toxicity, and secreted factors. These advanced gene-transfer tools may allow the testing of multiple modifications leading to more effective therapy processes. Moreover, high-quality assays, process innovations including cloud-based data transfer, and tracking and validating each step of manufacturing contribute to the increased demand for CAR T-Cell therapy in coming years.
The CAR T-cell therapy market is segmented by drug type {Abecma [idecabtagene vicleucel], Breyanzi [lisocabtagene maraleucel], Kymriah [tisagenlecleucel], Tecartus [brexucabtagene autoleucel], Yescarta [axicabtagene ciloleucel], and Carvykti [ciltacabtagene autoleucel]}, Target Antigen (CD, BCMA, HER2, Other Target Antigens), indication (lymphoma, acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, multiple myeloma, acute myeloid leukemia, other indications), and geography. The study also evaluates industry competitors and analyzes the regional and country-level markets.
Request Customization Here:
https://www.meticulousresearch.com/request-customization/cp_id=5508
Based on drug type, in 2023, the Yescarta (axicabtagene ciloleucel) segment is expected to account for the largest share of the CAR T-cell therapy market. The axicabtagene ciloleucel is used to treat B-cell lymphoma in adults. It helps overcome the body's immune system's weaknesses in cancer elimination, such as potentially poor T-cell function and inadequate amounts of tumor-specific T-cells, contributing to the large market share of this segment.
Based on target antigen, in 2023, the CD target antigen segment is expected to account for the largest share of the CAR T-cell therapy market. CD antigens are commonly found as surface antigens in various cancer cases. Hence, the therapy developed was particularly against CD antigens, contributing to the large market share of this segment.
Based on indication, in 2023, the lymphoma segment is expected to account for the largest share of the CAR T-Cell therapy market. The large market share of this segment is attributed to the increased number of lymphoma patients adopting CAR T-cell therapy as their treatment over others due to its effectiveness and positive results.
Geographic Review
This research report analyzes major geographies and provides a comprehensive analysis of North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, and the Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), Latin America, and the Middle East & Africa. In 2023, North America is expected to account for the largest share of the CAR T-cell therapy market, followed by Europe and Asia-Pacific. Advanced healthcare infrastructure in the U.S. and Canada, the high adoption of advanced technologies, highly skilled professionals available for performing cancer treatment research studies and clinical studies, and the growing number of approvals boost the growth of this market in North America.
Key Players
The key players operating in the CAR T-cell therapy market are Novartis AG (Switzerland), bluebird bio, Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Caribou Biosciences, Inc. (U.S.), Cartesian Therapeutics, Inc. (U.S.), Pfizer Inc. (U.S.), Cellectis S.A. (France), Celyad Oncology SA (Belgium), Gilead Sciences, Inc. (U.S.), Intellia Therapeutics, Inc. (U.S.), Merck & Co., Inc. (U.S.), Amgen Inc. (U.S.), Inovio Pharmaceuticals, Inc. (U.S.), and OncoTherapy Science, Inc. (Japan).
You can Buy Report from Here:
https://www.meticulousresearch.com/Checkout/37146980
Key questions answered in the report-
- Which are the high-growth market segments in terms of drug type, target antigen, indication, and geography?
- What was the historical market for CAR T-cell therapy across the globe?
- What are the market forecasts and estimates for the period 2023–2030?
- What are the major drivers, restraints, opportunities, and challenges in the CAR T-cell therapy market?
- Who are the major players in the CAR T-cell therapy market?
- What is the competitive landscape, and who are the market leaders in the CAR T-cell therapy market?
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Please login to comment on this Post